Hims & Hers Health (HIMS) is a highly rated stock with high implied volatility, which means high option premiums. Selling a Nov. 21, 50-strike put would generate around $555 in premium with HIMS stock trading around 54.38. The put seller would have the obligation to purchase 100 shares of Hims & Hers Health stock at 50 if called upon to do so by the put buyer. The break-even price for the trade can be calculated by taking the strike price less the premium received, which in this case gives a break-even pric ...

Key Takeaways HIMS integrates telehealth, EMRs and AI to deliver personalized, subscription-based healthcare.Hims & Hers plans to enter Canada in 2026, pairing generic treatments with digital care programs.A new CTO appointment highlights HIMS' focus on scaling AI-driven care personalization.The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) , operates on a digital-first, consumer-centric healthcare model that integrates telehealth technology, personalized treatment and a vertically ...

Listen and subscribe to The Big Idea with Elizabeth Gore on Apple Podcasts, Spotify, or wherever you find your favorite podcast. How do you break into a tough market and win? This CEO has done it twice. This week on The Big Idea with Elizabeth Gore, Dutch Pet, Inc. founder and CEO Joe Spector joins the show to answer the question: How can I break into a complex market? Spector, also the co-founder of the public health company Hims & Hers (HIMS), transformed the telehealth sector for both humans and animals ...

But I think with survivorship and entrepreneurship, >> yeah, >> it's simply just if you be down, you got to get up. You got to get up. You got to keep putting one foot in front of the other.And I think my thing is one of my like secret sauce things is perseverance. How y'all. I'm Elizabeth Gore.Welcome to The Big Idea from Yahoo Finance, the show that navigates the world of small business and entrepreneurship. All businesses start with one light bulb moment, and I'm going to take you on a journey with Ameri ...

Core Insights - Hims & Hers Health Inc. (NYSE:HIMS) has seen a significant stock price increase of 5.86% to close at $57.97, driven by leadership changes and global expansion initiatives [1][3]. Leadership Changes - CEO Andrew Dudum announced Mike Chi as the new Chief Operating Officer, effective November 2, 2025, replacing Nader Kabbani, who will transition to an advisory role focusing on global initiatives [2][3]. - Chi has been with Hims & Hers since 2021, while Kabbani joined in May 2025 [4]. Strategic Focus - The leadership changes are part of the company's strategy to scale operations and enhance innovation in tech and healthcare sectors [3].

Hims & Hers (NYSE: HIMS ) is one of the main players in the telehealth industry. You can go online, describe your symptoms, meet with healthcare professionals, and subscribe to a vast variety of treatments, all from behind your ownI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an a ...

Hims & Hers Health (HIMS) has formed a cup-with-handle base that offers a buy point at 60.55. The stock had surged 126% year-to-date, as of Monday, according to IBD MarketSurge. Hims stock is Tuesday's selection for IBD 50 Stocks To Watch. This is an early-stage base that can net higher gains that later ones do. Hims & Hers Health makes… Related news Breakout Stocks Watch: What Looms For October? 10/01/2025As October gets underway with market indexes near record highs, these stocks to watch highlight rules ...

Key Points The company is replacing its COO. It disclosed this in a regulatory document. 10 stocks we like better than Hims & Hers Health › The market often gets worried when a company announces a major change in its C-suite. On news that it was doing just that, on Friday the stock of consumer healthcare company Hims & Hers (NYSE: HIMS) was whacked with a more than 9% sell-off by investors. This occurred on a relatively stable day for the broader market, as the benchmark S&P 500 (SNPINDEX: ^GSPC) b ...

Core Insights - Hims & Hers Health, Inc. (HIMS) operates a subscription-based revenue model that provides predictable cash flows through ongoing treatments and services [1][3] - The company is expanding its offerings into new categories such as weight loss, dermatology, mental health, and sexual health, which are designed to deepen customer engagement and broaden the subscriber base [2][7] - Hims & Hers emphasizes long-term customer relationships, prioritizing lifetime value and predictable revenues, which enhances customer loyalty and trust [3] Revenue Model - Hims & Hers generates revenue primarily through subscriptions that cover prescription medications, wellness products, and provider consultations [1][7] - The subscription plans offer flexible delivery schedules ranging from 30 to 360 days, allowing customers to tailor their experience [1] - The integrated technology platform streamlines the customer journey, enhancing operational efficiency and gross margins [1][3] Growth Strategy - The company’s expansion strategy is supported by the addition of new product categories that require recurring treatments, thereby attracting new customers and encouraging cross-selling [2][3] - Recent product launches, including exclusive testosterone offerings, aim to deepen engagement with existing subscribers [2][7] Financial Performance - Hims & Hers shares have increased by 139.4% year-to-date, significantly outperforming the industry growth of 38.9% [6] - The Zacks Consensus Estimate predicts a 122.2% improvement in earnings per share for 2025 compared to 2024 [8][11] - Hims & Hers has a forward 12-month price-to-sales ratio of 4.9X, which is lower than the industry average of 6.1X but higher than its three-year median of 2.5X [10]

Hello, I'm Frank Colin, anchor Worldwide Exchange. Every morning on the show, we have a stock pick. Today's pick was Hims and Hers Health.It came from Vance Howard of Howard Capital Management. He says he likes this name because of its base of subscription revenue, in particular tied to its GLP1 weight loss drug business. Uh stock has a lot of momentum.It's up more than 35% over the last month. Howard says he likes that momentum and also the fact that the stock has continued to move higher even after it rec ...